Adaptive Phase I & II Trials

Rapid approval, flexible conduct, adaptive protocols in a MHRA accredited facility.

View service

Phase III Clinical Studies

Fast and efficient patient recruitment for Phase III clinical trials.

View service

TQT Studies

Cardiac safety assessments are built into every clinical study.

View service

Bridging Studies

Fast track your global marketing authorisations with our ethnic bridging studies.

View service

Patient Recruitment

Fast and efficient in-house team, specialising in patient recruitment.

View service

Data Management

Flexible, efficient and tailored to our clients’ needs.

View service

Gene Editing & Gene Silencing

Richmond Pharmacology is at the forefront of gene editing.

View service

Latest news

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

Events

Swiss Biotech Day 2025

5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event